Breast Cancer Cases Continue to Grow as Effective Screening Boosts Survival Rates

GlobalData shares the following press release on the growth of breast cancer over the next ten years.

LONDON, UK (GlobalData), 11 December 2013 – The total number of breast cancer incident cases in the nine major markets (9MM) — the US, France, Germany, Italy, Spain, UK, Japan, urban China and Brazil — is expected to increase by 44% over the next decade, from 0.90 million in 2012 to 1.29 million by 2022, forecasts research and consulting firm GlobalData.

The company’s latest report* states that the number of five-year prevalent cases of breast cancer will also grow by 44%, climbing from 3.7 million in 2012 to 5.39 million by 2022. Out of the 9MM, the US and urban China had the highest number of five-year prevalent cases in 2012, with 1.15 million and 898,406 cases, respectively.

Samantha Lee, GlobalData’s Epidemiologist, says: “The forecast growth in breast cancer incidence is partly due to rising cases of obesity, growing detection through screening programs, and changes in reproductive patterns and the use of postmenopausal hormone replacement therapy.”

According to the World Health Organization, increased breast cancer survival has contributed greatly to the prevalence of the disease, and there is a large amount of evidence showing that breast cancer mammographic screening is effective in reducing the disease mortality by at least 20% in women aged 50 years and older. Lee says: “Prevention measures taken to improve breast cancer survival in parts of the world where organized nationwide mammography screening has only been made available in recent years, such as Brazil and China, will boost survival rates and impact the disease incidence and prevalence in those countries.”

Nonetheless, GlobalData epidemiologists expect the impact of screening for breast cancer,  in these markets, to be limited in the short term. This is due to the lack of sufficient resources and infrastructure needed to support the downstream healthcare needs associated with screening, such as additional diagnostic tests and treatment.

*EpiCast Report: Breast Cancer – Epidemiology Forecast to 2022 -This report provides an overview of the risk factors and global trends of invasive breast cancer in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and urban China). It includes a 10-year epidemiological forecast for the incident cases, and five-year prevalent cases, of breast cancer in women segmented by age, natural menopausal status, cancer stage at diagnosis, and hormone receptor subtypes. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

Source: GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Rearch and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling GlobalData to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact GlobalData Press Office on +44 (0)1204 543 528 or at pr@globaldata.com.